news
Dual antibodies effective against SARS-CoV-2 variants in animal study
In mice and hamsters, therapies made from two antibodies were found to be mostly effective against a range of SARS-CoV-2 variants.
List view / Grid view
Covid-19
article
Screening for COVID-19 drugs
With the COVID-19 pandemic ongoing, new therapeutic drugs to combat SARS-CoV-2 are still required. In this article, Professor Arvind Patel from the Medical Research Council (MRC) – Centre for Virus Research (CVR) at the University of Glasgow spoke with Drug Target Review’s Victoria Rees to discuss the work being done…
article
Assessing compound activity to accelerate drug discovery
In this article, Drug Target Review’s Victoria Rees explores a new screening platform that assesses the biological activity of molecules to identify potential drugs. Using their new technique, researchers from the US National Institutes of Health (NIH) identified potential COVID-19 therapeutics.
news
Intestinal bacteria found to produce SARS-CoV-2-inhibiting compounds
Researchers have screened bacteria in the gut, finding that Bifidobacteria have inhibitory activity against SARS-CoV-2.
article
Better therapeutic antibodies by design
The binding specificity and high binding affinity of therapeutic antibodies makes them an ideal therapy for treating a wide range of human disorders. Advancements in antibody technologies have resulted in huge development success along with a boost in novel and improved treatment strategies. However, specific challenges and considerations are faced…
article
How to mix the best anti-SARS-CoV-2 cocktail
Neutralisation resistance generated by Spike (S) protein mutations in Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) poses a challenge to antibody therapies for COVID-19. Antibody cocktails targeting the S protein receptor binding domain (RBD) are one way to avoid viral neutralisation escape, however only certain antibody combinations are currently effective.…
article
Digital revolution – not evolution – is the route to building back stronger after COVID-19
With a return to the workplace on the horizon for an increasing number of scientists, Richard Goodwin considers how COVID-19 will impact the ways research is conducted. One outcome he posits is the acceleration of the digital transformation that was already occurring in pharmaceutical R&D.
news
Nanodecoy therapy neutralises SARS-CoV-2 in macaques
Lung spheroid cells can act as nanodecoys for the SARS-CoV-2 Spike protein to bind to, according to a new pre-clinical study.
news
Researchers visualise metabolic processes at the single-cell level
Scientists have used imaging methods and machine learning to understand cellular metabolism at the single-cell level.
news
Stem cells may be key for new vaccines against COVID-19
Scientists say COVID-19 may activate tuberculosis infection, but stem cell-mediated defence mechanisms could be targeted to develop vaccines.
news
Two COVID-19 vaccines show safety and strong immunity in infant model
Two groups of infant rhesus macaques received one of two potential COVID-19 vaccines, which were shown to elicit high levels of neutralising antibodies.
news
Very long-chain fatty acids found to block SARS-CoV-2 infection
Researchers have shown that omega-3 very long-chain polyunsaturated fatty acids can block SARS-CoV-2 and protect lung cells.
news
Researchers link SARS-CoV-2 PLpro to COVID-19 symptoms
Researchers have shown that the SARS-CoV-2 PLpro cuts human proteins so could potentially cause a range of COVID-19 symptoms.
news
Nanoparticle platform enables enhanced delivery of gene therapies
Scientists have created new nanoparticle-based materials that could be used to deliver gene therapies in an adaptable way.
news
Senolytic drugs reduce COVID-19 symptoms in mice, study shows
In pre-clinical studies, senolytic drugs were found to reduce inflammation and death from COVID-19 in older mice.
